Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy

Yuen, Man‐Fung; Heo, Jeong; Kumada, Hiromitsu; Suzuki, Fumitaka; Suzuki, Yoshiyuki; Xie, Qing; Jia, Jidong; Karino, Yoshiyasu; Hou, Jinlin; Chayama, Kazuaki; Imamura, Michio; Lao-Tan, Judy; Gee Lim, Seng; Tanaka, Yasuhito; Xie, Wen; Yoon, Jung‐Hwan; Duan, Zhongping; Kurosaki, Masayuki; Park, Sung-Jae; Eternity Labio, Madalinee; Kumar, Rajneesh; Kweon, Young-Oh; Joon Yim, Hyung; Yu, Tao; Cremer, Jennifer; C. Elston, Robert; Davies, Matt; Baptiste‐Brown, Sharon; Han, Kelong; Campbell, Fiona; Paff, Melanie; Theodore, Dickens

doi:10.1016/j.jhep.2022.05.031

Public

Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy

Published in Journal of Hepatology • Jun 14, 2022

Authors:

Man‐Fung Yuen

Jeong Heo

Hiromitsu Kumada

Abstract

Background & Aims Bepirovirsen, an antisense oligonucleotide targeting pregenomic and mRNA transcripts of HBV, has been conjugated to N -acetyl galactosamine (GSK3389404) to enhance hepatocyte delivery. This dose-finding study was the first to assess GSK3389404 for chronic HBV infection. Methods Thi...

Subject

Medicine

Placebo

HBsAg

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!